Will 2022 Be US FDA’s Year Of ‘No’? Approval Rate For Novel Agents Plunged In First Half

 
• By Bridget Silverman
FDA first-half plunge
APPROVALS HAVE TAKEN A DIVE IN THE FIRST HALF OF THE YEAR, BUT SECOND-HALF NUMBERS TEND TO BE HIGHER. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

More from US FDA Performance Tracker

More from Regulatory Trackers